These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

752 related items for PubMed ID: 9364988

  • 21. Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores.
    Kotian PL, Krishnan R, Rowland S, El-Kattan Y, Saini SK, Upshaw R, Bantia S, Arnold S, Babu YS, Chand P.
    Bioorg Med Chem; 2009 Jun 01; 17(11):3934-58. PubMed ID: 19409795
    [Abstract] [Full Text] [Related]

  • 22. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA, Gouripur VV, Gadad AK.
    Bioorg Med Chem; 2005 Apr 15; 13(8):2773-82. PubMed ID: 15781388
    [Abstract] [Full Text] [Related]

  • 23. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
    Deinum J, Mattsson C, Inghardt T, Elg M.
    Thromb Haemost; 2009 Jun 15; 101(6):1051-9. PubMed ID: 19492147
    [Abstract] [Full Text] [Related]

  • 24. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry.
    Ostrem JA, al-Obeidi F, Safar P, Safarova A, Stringer SK, Patek M, Cross MT, Spoonamore J, LoCascio JC, Kasireddy P, Thorpe DS, Sepetov N, Lebl M, Wildgoose P, Strop P.
    Biochemistry; 1998 Jan 27; 37(4):1053-9. PubMed ID: 9454596
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH, Rijken DC.
    Thromb Haemost; 2004 Mar 27; 91(3):473-9. PubMed ID: 14983222
    [Abstract] [Full Text] [Related]

  • 27. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation?
    Stürzebecher J, Stürzebecher U.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Mar 27; 115(1-2):152-6. PubMed ID: 2459011
    [Abstract] [Full Text] [Related]

  • 28. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM.
    J Pharmacol Exp Ther; 2000 Jan 27; 292(1):351-7. PubMed ID: 10604970
    [Abstract] [Full Text] [Related]

  • 29. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
    Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M.
    Thromb Haemost; 1994 Mar 27; 71(3):314-9. PubMed ID: 8029795
    [Abstract] [Full Text] [Related]

  • 30. Serine protease specificity for peptide chromogenic substrates.
    Mattler LE, Bang NU.
    Thromb Haemost; 1977 Dec 15; 38(4):776-92. PubMed ID: 146272
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain.
    Lee SL, Alexander RS, Smallwood A, Trievel R, Mersinger L, Weber PC, Kettner C.
    Biochemistry; 1997 Oct 28; 36(43):13180-6. PubMed ID: 9341205
    [Abstract] [Full Text] [Related]

  • 34. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
    Quan ML, Ellis CD, Liauw AY, Alexander RS, Knabb RM, Lam G, Wright MR, Wong PC, Wexler RR.
    J Med Chem; 1999 Jul 29; 42(15):2760-73. PubMed ID: 10425087
    [Abstract] [Full Text] [Related]

  • 35. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J, Deng H, Jin L, Pandey P, Quinn J, Cantin S, Rynkiewicz MJ, Gorga JC, Bibbins F, Celatka CA, Nagafuji P, Bannister TD, Meyers HV, Babine RE, Hayward NJ, Weaver D, Benjamin H, Stassen F, Abdel-Meguid SS, Strickler JE.
    J Med Chem; 2006 Dec 28; 49(26):7781-91. PubMed ID: 17181160
    [Abstract] [Full Text] [Related]

  • 36. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity.
    Berry CN, Lassalle G, Lunven C, Altenburger JM, Guilbert F, Lalé A, Hérault JP, Lecoffre C, Pfersdorff C, Herbert JM, O'Connor SE.
    J Pharmacol Exp Ther; 2002 Dec 28; 303(3):1189-98. PubMed ID: 12438543
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP, Bernat A, Gaich C, Herbert M.
    Thromb Haemost; 2002 Feb 28; 87(2):238-44. PubMed ID: 11858483
    [Abstract] [Full Text] [Related]

  • 39. Tetrahydro-isoquinoline-based factor Xa inhibitors.
    Kucznierz R, Grams F, Leinert H, Marzenell K, Engh RA, von der Saal W.
    J Med Chem; 1998 Dec 03; 41(25):4983-94. PubMed ID: 9836616
    [Abstract] [Full Text] [Related]

  • 40. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
    Wong PC, Crain EJ, Knabb RM, Meade RP, Quan ML, Watson CA, Wexler RR, Wright MR, Slee AM.
    J Pharmacol Exp Ther; 2000 Oct 03; 295(1):212-8. PubMed ID: 10991981
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.